| INTRODUCTION
Mediastinal and hilar lymphadenopathy (MHLE), defined as lymph nodes with short axis >10 mm, are common findings on computed tomography (CT) in patients with extra-pulmonary malignancies (EPM).
In a newly diagnosed EPM, they may indicate distant metastasis (M1 stage) and may be the first sign of malignancy in an occult EPM. 1 In patients with previously diagnosed and treated EPMs, new-onset MHLE may indicate disease relapse, an occult second primary malignancy, or an undetected granulomatous disease. In patients with EPMs who develop lung metastasis, coexistent MHLE is seen in~28% of cases. 2 Confirmation of lymph node metastases is important in these patients as it significantly worsens prognosis and precludes any possible benefit of lung metastasectomy. 3 Increased 2-fluoro-2-deoxy-D-glucose uptake on positron emission tomography (PET) is fairly sensitive for metastases (~65%). 4 However, a significant proportion of infectious and inflammatory diseases also show increased PET uptake, lowering its specificity (~35%) and diagnostic accuracy (~65%) for malignancy. 5 Thus, histopathological characterisation of MHLE is warranted for accurate staging, prognostication, and treatment in patients with known EPMs, and preliminary tissue diagnosis in cases with unknown primary.
Sampling of MHLE can be performed by invasive procedures such as thoracotomy and cervical mediastinoscopy, or minimally invasive procedures such as conventional transbronchial needle aspiration/ biopsy (TBNA), endoscopic ultrasound-guided fine needle aspirate and, more recently, endobronchial ultrasound-guided (EBUS)-TBNA.
EBUS-TBNA as a single procedure allows access to maximum lymph nodes stations (stations 1, 3, 4, 7, 10-12), including hilar and lobar lymph nodes inaccessible by most others. It can also evaluate centrally located lung masses and can be performed at the same time as flexible bronchoscopy. 6 However, unlike other modalities compatible with the 19-gauge core biopsy needle, EBUS-TBNA procedures use only 21 or 22-gauge needles that are better suited for aspiration cytology. Histological cores (blood clot cores or BCC) can be obtained from suctioning of the needle, but they are smaller than a true core biopsy. 7 Nevertheless, cytological samples obtained using EBUS-TBNA procedures have been found to yield histological and molecular diagnostic information comparable to small biopsies. [8] [9] [10] [11] [12] Being minimally invasive, safe, costeffective and highly sensitive (~93%), 8 EBUS-TBNA has now replaced mediastinoscopy as the first-line investigative modality for lymph node staging of patients with non-small cell lung carcinoma.
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Role of EBUS-TBNA in sampling mediastinal lymph nodes and masses in patients with EPMs has been evaluated in a few clinical studies previously, with variable sensitivities (81%-95%) and negative predictive values (73%-92%) reported. 5, [16] [17] [18] [19] [20] [21] [22] We performed a retrospective review of all EBUS-TBNA-guided aspirates received in our department from patients with suspected, newly diagnosed or previous history of EPMs. Our objectives were to evaluate the diagnostic utility and limitations of EBUS-TBNA-guided aspirates in these patients with an aim to identify possible measures to improve yield from the perspective of a cytopathologist. 
| METHODS

| Diagnostic yield of EBUS-TBNA
Endobronchial ultrasound-guided transbronchial needle aspiration yielded adequate material in 110 patients (79%). Malignancy was detected in 69 patients (50%), granulomatous inflammation was seen in 20 patients (14%) and only reactive lymphoid tissue was obtained in 21 patients (15%) (Figure 1 ).
| EBUS-TBNA findings in patients with known EPM
In the 100 patients with known EPM, metastasis/relapse was con- Granulomatous mediastinal lymphadenopathy was detected in 16 patients (Figure 2 ). Acid-fast bacilli were detected in one of these patients who had undergone total thyroidectomy and neck dissection for papillary thyroid carcinoma, confirming tuberculosis (TB).
Acid-fast stain and microbiological cultures for TB were negative in the remaining cases, and no follow-up biopsies were available. One patient with metastatic breast carcinoma showed tumour along with granulomas in the corresponding BCC ( Figure 3D-F) .
Among the 55 patients with negative/unsatisfactory EBUS-TBNA, follow-up biopsy from the same mediastinal lymph nodes was not performed in any. However, follow-up resection/biopsies from other sites were available in 12 patients ( 
| EBUS-TBNA findings in patients with known lymphoma
Of the six patients with known HL, EBUS-TBNA confirmed relapse in two patients. In both, the cytomorphology was characteristic enough for definitive diagnosis of HL ( Figure 3J-L) . EBUS-TBNA yielded reactive lymphoid tissue in one patient and was unsatisfactory in three patients (Figure 1 ). In one of the three patients with unsatisfactory EBUS-TBNA, HL relapse was eventually confirmed on an abdominal lymph node biopsy. Follow-up biopsies were not available in the remaining patients.
Among the five patients with known NHL, relapse of DLBCL was detected in one, while the remaining four patients showed evidence of granulomatous inflammation. Two of them also harboured acidfast bacilli, confirming TB.
| EBUS-TBNA findings in patients with suspected EPM
Among 28 patients with suspected EPM with no known primary, EBUS-TBNA detected malignancy in 21 patients ( Figure 1, Table 2 ).
Tissue was adequate for ICC in 16 of these patients and was able to better characterise type and possible primary site of malignancy in 12 cases, while the remaining four poorly differentiated malignant tumours could not be characterised on the limited ICC panels done (Table 2 were all diagnosed solely on EBUS-TBNA supported by ICC testing (Table 2 ). Reactive lymphoid tissue was obtained in two patients, while EBUS-TBNA was inadequate in the remaining five patients.
Two of the latter were eventually diagnosed with an endobronchial mucoepidermoid carcinoma and small cell carcinoma of bladder (Table 2 ). suspected EPMs constitutes~10%-16% of all indications for which patients undergo EBUS-TBNA. 17, 25 Metastases are identified in only 40%-50% of these patients, [16] [17] [18] [19] [20] [21] [22] of whom 5%-23% patients are found to harbour a second primary malignancy, most commonly in the lung. 5, 17, 18, 21, 22 A significant proportion (9%-20%) have granulomatous diseases, 5, 16, 20, 21, 25 further characterised as TB (2%-9%) or sarcoidosis in few studies. 5, 25 Each of these diagnoses requires drastically different treatments. Positive EBUS-TBNA results have been found to alter treatment procedures in 55% 16 and obviate invasive surgical procedures in 60%-87% 17, 21, 26 of patients with EPM. In our study, we found metastases in 45% and granulomatous inflammation in 16% of patients with proven EPMs. While the presence of acid-fast bacilli confirmed BT in one patient, it is likely that TB constitutes a larger proportion of the granulomatous lesions identified in our cohort, given the high prevalence of TB in our country and the low sensitivity of the acid-fast stain for detection of Mycobacterium tuberculosis.
| Value of EBUS-TBNA BCC
False-positive results for malignancy by EBUS-TBNA are extremely uncommon, although are theoretically possible if the aspirate needle passes through bronchial mucosa harbouring high-grade dysplasia or carcinoma-in-situ. 24 The positive predictive value of EBUS-TBNA for malignancy is near 100% 3 and patients usually do not require further work-up, except when EBUS-TBNA material is inadequate for proper characterisation or biomarker testing. In our cohort,
we observed that at least 25% of patients with suspected EPM of unknown primary with positive EBUS-TBNA results required additional biopsies or repeat sampling due to lack of material for ancillary ICC testing.
False-negative EBUS-TBNA results are not uncommon. In previous studies, patients with a negative EBUS-TBNA result (reactive/ T A B L E 2 Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) findings in patients with suspected extrapulmonary malignancy with no known primary site granulomatous/inadequate) underwent mediastinoscopy/additional surgical biopsies or were kept on radiological follow-up for 6-18 months to look for progressive lymph node enlargement. 5, [16] [17] [18] [19] [20] [21] [22] Malignancy was eventually detected in 9-27% of these patients and the NPV of EBUS-TBNA for malignancy ranged from 73% to 92%. In general, lymph nodes ≥5 mm are considered pathological in EBUS-TBNA procedures. 3 For every 1-mm increase in the size of the lymph node, the probability of malignancy in a patient with known EPM increases by 4%, 26 with lymph nodes >20 mm showing 100% rate of metastases in some series. 3, 5 However, one study found that patients with co-morbid medical illnesses such as heart failure tend to harbour larger reactive lymph nodes. 27 Anthracotic lymph nodes can also present as MHLE, constituting 15%-20% of MHLE in patients with EPM in two series. 15, 27 One study compared the number of lymph node stations involved and found that sarcoidosis invariably involved more than three lymph node stations as compared to TB, lymphomas or metastatic carcinomas that involved one to three stations. 27 Further studies are required to determine effective stratified follow-up strategies for patients with negative EBUS-TBNA results. 27 Our series also included 11 patients with proven lymphomas in whom EBUS-TBNA detected relapse and granulomatous inflammation in nearly equal proportions. EBUS-TBNA also identified two cases of de-novo HL. Historically, the sensitivity of EBUS-TBNA has been considered to be low in lymphoreticular malignancies (33%) as compared to carcinomas (100%) or granulomatous disorders (80%-95%). 27 However, more recent studies have found high sensitivity (~90%) in diagnosing de novo or relapsed lymphoma. 28, 29 Definitive diagnosis of HL is possible by EBUS-cytology alone, while subtyping of NHL requires ancillary testing. 28 When judicious case assessment is made during ROSE and additional samples are obtained for ICC and flow cytometry, the sensitivity of EBUS-TBNA in subtyping NHL can reach up to 90%. 29 In our study, all four cases of HL (2-relapse and 2-denovo) were diagnosed confidently on EBUS-TBNA aspirates.
The rate of inadequate EBUS-TBNA was~20% in our series, which is higher than what has been observed in previous similar studies, including some where ROSE was not performed. 5, 20, 27 ROSE was not uniformly available in all of our cases. Further, being a teaching hospital, trainees frequently performed the procedures (both EBUS-TBNA and ROSE) and their learning curves may account for these differences.
For a cytopathologist, EBUS-TBNA samples from patients with suspected/known EPMs pose special challenges. Relevant ICC to confirm the primary site is required in most metastatic adenocarcinomas and in nearly all cases with unknown primary and poorly differentiated morphology. In metastatic melanomas and breast carcinomas, predictive biomarker testing may be requested. In new primary lung carcinomas, these samples represent a source for molecular testing. 21 In treated lymphomas with mediastinal fibrosis, EBUS-TBNA may be only the investigative procedure possible to confirm relapse. The role of the on-site cytopathologist cannot be over-emphasised and obtaining appropriate samples, including for microbiological, flow cytometry and molecular testing, based on the clinical history and on-site evaluation is a major determinant of the success of EBUS-TBNA procedures. Evaluation of the BCC is of additional value, as seen in our study.
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| CONCLUSION
Our study is one of the largest series to date, analysing the role of EBUS-TBNA in patients with EPM. EBUS-TBNA confirmed malignancy in~50% patients and was unsatisfactory in~20% cases. ICC testing is usually required in most of these patients and obtaining adequate material for ancillary testing is necessary for arriving at a timely diagnosis and reducing need for additional investigations.
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